Fiona Rutherford
@Fi_Rutherford
US Healthcare Reporter / [email protected]
ID:66663235
https://www.bloomberg.com/authors/ATkNo11cclo/fiona-rutherford 18-08-2009 12:04:21
6,7K تغريدات
8,0K متابعون
1,8K التالية
I'm thrilled that the body of work on the FDA's speedy drug approvals that I've been working on with Robert Langreth won third place in the Awards for Excellence in Health Care Journalism.
Thank you Association of Health Care Journalists for recognizing our work on this issue healthjournalism.org/contest-entry/…
Americans are spending billions on drugs that don’t work because of the FDA’s drive to get new medications to patients quickly bloomberg.com/news/articles/… My latest reporting on the FDA's expedited drug approval pathways w/
Robert Langreth
Tanaz Meghjani
'We get drugs faster and faster and know less and less about them and pay more and more.' Terrific reporting from Robert Langreth Fiona Rutherford Tanaz Meghjani bloomberg.com/news/articles/…
Generic drugs are supposed to be affordable and safe. Instead, they’re cheap—but sometimes dangerous. Anna Edney and Riley Ray Griffin reveal why. Check out the latest in our Bad Medicine series bloomberg.com/news/features/…
Food and Drug Administration Deputy Commissioner Dr. Janet Woodcock will retire next year after nearly four decades at the regulator.
Woodcock confirmed the news in an email.
More here from Fiona Rutherford Jeannie Baumann & Nyah Phengsitthy: news.bloomberglaw.com/health-law-and…
A cancer drug got a short-cut approval from the FDA 14 years ago. Officials still aren’t sure that it works. Fiona Rutherford Robert Langreth bloomberg.com/news/articles/…
Today's Big Take: People are taking drugs every day that haven’t met the FDA’s normal standards. Robert Langreth, Fiona Rutherford, Immanual John Milton and Madeline Campbell found 19 drugs with accelerated approvals whose trials are still listed as delayed. bloomberg.com/news/articles/… via Bloomberg
Perrigo’s birth-control product Opill faces a critical hurdle next week after US regulators raised concerns about whether it would be suitable as an over-the-counter drug, reports Fiona Rutherford. ⬇️ bloomberg.com/news/articles/…
Makena - the only drug approved in the US to reduce the risk of premature birth - will be immediately pulled from the market due to a lack of effectiveness bloomberg.com/news/articles/… w/ Robert Langreth
Pharmacy chains are on the front lines as the abortion pill becomes a new battleground in the reproductive-rights fight.
Almost 100 protests are planned against Walgreens, CVS & Rite Aid, which aim to sell the pills where it's legal bloomberg.com/news/articles/… For Businessweek w/ Brendan Case
Americans have been reluctant to get frequent Covid boosters, but FDA advisers are meeting today to discuss a 'simplified' approach that might get shots down to once per year.
Follow along here with updates from Fiona Rutherford + Tanaz Meghjani: bloomberg.com/news/articles/…
Frank Yiannas, the top US food safety official, said he’ll step down next month, departing after an extended controversy over infant formula.
He cited concerns about the decentralized structure of the foods program.
More here with Fiona Rutherford
news.bloomberglaw.com/health-law-and…
Rite Aid is the latest pharmacy to say it will sell abortion pills at its stores. Walgreens and CVS previously said they would provide the drug to patients, who will be able to get it in-person of via mail. bloomberg.com/news/articles/… via Fiona Rutherford
The FDA has cleared lecanemab (Leqembi) - the first treatment clearly shown to slow the advance of Alzheimer’s disease.
The drug will cost $26,500 a year for a person of average weight, Eisai says bloomberg.com/news/articles/… w/ Robert Langreth
NEW from Fiona Rutherford Robert Langreth:
FDA gives accelerated approval to Eisai/Biogen‘s Alzheimer’s drug. It is the first to clearly slow the disease in trials.
bloomberg.com/news/articles/…